Escitalopram, Duloxetine, Agomelatine Beat Fluoxetine in Antidepressant Review

Depression symptoms persisted less often for patients taking specific medications in a new review published in The Lancet Psychiatry.

Researchers examined 115 randomized controlled trials encompassing over 30,000 participants. The analysis evaluated 21 antidepressants to determine which formulas best maintained symptom reduction over the long term.

Patients prescribed escitalopram, duloxetine, and agomelatine reported improved symptom control more frequently than individuals taking fluoxetine. Individuals using escitalopram and duloxetine also maintained their medication regimens at higher rates during the trials.

“Escitalopram is already widely used,” Paul van Haaren, a researcher at Radboud University Medical Center in the Netherlands, said in a news release.

Medication Comparisons and Trial Data

The mean age of study participants was 45 years, with 66% identifying as women. The primary network meta-analysis evaluated 35 head-to-head trials involving 9,888 participants across 14 different antidepressants.

Compared to fluoxetine as a reference drug, the odds ratios for a sustained treatment response were 1.62 for escitalopram, 1.57 for duloxetine, and 1.40 for agomelatine. Furthermore, escitalopram and duloxetine showed significantly lower all-cause discontinuation rates than fluoxetine, with respective odds ratios of 0.60 and 0.64.

Nineteen of the 35 primary trials analyzed carried a high risk of bias. More than half of the studies included in the broader review shared similar methodological limitations, indicating that some performance gaps between medications may stem from original trial constraints.

A young woman sits on a sofa and holds a cold drink in one hand and a pill in the other. She is about to take her tablet
Photo: BBC

Clinical Guidelines and Prescription Patterns

Clinical guidelines recommend continuing antidepressant therapy for six to 12 months after achieving an acceptable response. Real-world utilization frequently exceeds this window, with Australian data indicating an average treatment duration of four years.

In 2024–2025, 3.8 million Australians received dispensed prescriptions for antidepressants. Escitalopram ranked 13th among all Pharmaceutical Benefits Scheme prescriptions during that period, while duloxetine ranked 45th. Agomelatine remains unavailable through the PBS.

“As a prescriber, you consider the balance between a medication’s benefits and side effects,” Eric Ruhé, a professor of difficult-to-treat depression at Radboud University Medical Center, said in a release. “That balance differs from person to person.”

Treatment Selection Factors

Average outcomes across trial groups do not dictate individual responses. Tolerability involves balancing symptom relief against side effects that affect everyday life, such as sexual dysfunction, weight changes, or sleep disruptions.

“If you start an antidepressant, choose one that not only helps you to get well, but also keeps you well,” Ruhé said.

Bupropion and reboxetine showed lower sustained response rates than several alternative antidepressants in pairwise comparisons. Meanwhile, other common medications, including sertraline, performed no better than the fluoxetine baseline in maintaining long-term stability.

Patient discussing medication side effects
Photo: Medical Daily

Commonly Asked Questions About Long-Term Antidepressant Efficacy

How long were participants followed in the primary comparative trials?

The median follow-up duration for the primary head-to-head trials was 24 to 26 weeks, with only six trials tracking participants beyond six months.

Is agomelatine approved for use in the United States?

Agomelatine is not approved by the Food and Drug Administration and is not available in the United States.

What percentage of relapse-prevention trial participants maintained stability on medication versus placebo?

In a separate analysis of 39 relapse-prevention trials involving 10,428 participants, the sustained response rate reached 61.5% among those who continued antidepressants, compared to 44.7% among patients switched to a placebo.

“it cannot tell us which antidepressant will work best for an individual patient,” Dr Sameer Jauhar, an expert at Imperial College London, said.

Paul van Haaren, first author of the Lancet Psychiatry review and a researcher at Radboud University Medical Center in Nijmegen, led the international collaboration that synthesized evidence from 115 randomized controlled trials involving more than 30,000 participants. The analysis, conducted with colleagues from Amsterdam, Oxford, Kyoto, London, Osaka and Bern, represents the first large-scale network meta-analysis to compare 20 antidepressants against fluoxetine for sustained response over both short- and long-term use.

Does the study recommend that patients currently doing well switch their medication?

Researchers emphasized that the findings do not justify changing medications for individuals who are already responding well to their current prescription.